GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.